PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1758981
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1758981
Gonorrhea Therapeutics
Global Gonorrhea Therapeutics Market to Reach US$2.8 Billion by 2030
The global market for Gonorrhea Therapeutics estimated at US$2.0 Billion in the year 2024, is expected to reach US$2.8 Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. Monotherapy, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Combination Therapy segment is estimated at 4.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$531.7 Million While China is Forecast to Grow at 5.5% CAGR
The Gonorrhea Therapeutics market in the U.S. is estimated at US$531.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$451.0 Million by the year 2030 trailing a CAGR of 5.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.2% and 4.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.
Global "Gonorrhea Therapeutics" Market - Key Trends & Drivers Summarized
Why Is the Gonorrhea Therapeutics Market Regaining Urgency and Global Attention?
The global gonorrhea therapeutics market is regaining attention as the disease re-emerges as a public health challenge, particularly with rising antibiotic resistance. Gonorrhea, a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, continues to affect millions of individuals annually, with the highest prevalence among sexually active young adults. While the infection is typically treatable, growing resistance to cephalosporins and azithromycin-once the mainstays of treatment-has created an urgent need for new therapeutic strategies. The World Health Organization (WHO) and U.S. Centers for Disease Control and Prevention (CDC) have issued warnings about “super gonorrhea” strains, prompting increased investment in drug development, diagnostics, and global STI surveillance programs.
What Innovations Are Reshaping the Treatment Landscape for Drug-Resistant Gonorrhea?
In response to rising antimicrobial resistance, pharmaceutical companies and research institutions are accelerating efforts to develop next-generation therapies for gonorrhea. Novel antibiotics, such as zoliflodacin and gepotidacin, are currently in advanced clinical trials and show promise against multi-drug resistant strains. Meanwhile, repurposing of existing drugs, dual-therapy regimens, and combination treatments are being explored to enhance efficacy and delay resistance onset. Biotech firms are also investigating non-antibiotic approaches, including monoclonal antibodies, bacteriophage therapy, and host-directed therapeutics. Additionally, rapid point-of-care diagnostics are improving early detection and allowing clinicians to tailor treatments more effectively-critical for managing resistant infections and limiting disease transmission.
How Do Regional Health Systems and Awareness Campaigns Affect Market Dynamics?
The burden of gonorrhea is highest in low- and middle-income regions, particularly Sub-Saharan Africa, Southeast Asia, and parts of Latin America, where limited access to diagnostics and care impedes treatment. However, high-income regions like North America and Europe are also reporting a rise in cases, partly due to more robust surveillance systems and greater social awareness. Government-led STI prevention initiatives, sexual health education, and expanded testing are driving therapeutic demand in these areas. Programs offering free or subsidized treatment, combined with efforts to reduce stigma around STIs, are also increasing diagnosis rates and timely care. The global travel and migration landscape adds complexity, contributing to cross-border transmission and the need for coordinated international responses.
What Are the Primary Growth Drivers and Obstacles in the Gonorrhea Therapeutics Market?
The growth in the gonorrhea therapeutics market is driven by increasing infection rates, urgent public health mandates, and the emergence of resistant strains that demand new pharmaceutical interventions. Rising awareness of sexual health, government funding for STI control, and global collaboration in research are supporting market expansion. However, significant barriers persist, including the slow pace of antibiotic R&D, regulatory hurdles, high development costs, and limited commercial incentives for pharma companies to pursue STI-related products. Additionally, the social stigma associated with STIs can lead to underreporting and delayed treatment, complicating market dynamics. Nonetheless, growing pressure from global health agencies and innovation in both diagnostics and drug development signal a renewed and necessary push in advancing gonorrhea therapeutics.
SCOPE OF STUDY:
The report analyzes the Gonorrhea Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Therapy (Monotherapy, Combination Therapy); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 42 Featured) -
- AbbVie Inc.
- Alopexx Pharmaceuticals
- Amgen Inc.
- Apotex Inc.
- Astellas Pharma Inc.
- AstraZeneca plc
- Bayer AG
- Becton, Dickinson and Company
- Biolytics Pharma
- Bristol Myers Squibb Co.
- Cipla Ltd.
- Danaher Corporation
- Debiopharm International SA
- Dr. Reddy's Laboratories
- Eli Lilly and Company
- Entasis Therapeutics
- Evofem Biosciences, Inc.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Hikma Pharmaceuticals plc
- Hologic, Inc.
- Johnson & Johnson
- Lupin Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Microbiotix, Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Summit Therapeutics plc
- Teva Pharmaceutical Industries Ltd.
- Therapyx, Inc.
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Tariff Impact on Global Supply Chain Patterns
- Gonorrhea Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Incidence of Antimicrobial-Resistant Gonorrhea Strains Drives Urgency for New Therapeutics
- Pipeline Expansion of Dual-Action Antibiotics Strengthens Business Case for R&D in STI Therapies
- Increased Government Funding and WHO Priority Designation Throw Spotlight on Gonorrhea Research
- Advancements in Rapid Diagnostic Tools Accelerate Prescription of Targeted Treatments
- Public Health Campaigns and STI Awareness Programs Sustain Demand for Accessible Therapies
- Clinical Trials of Novel Antibiotic Classes and Phage Therapy Open New Treatment Frontiers
- Global Urbanization and High-Risk Population Growth Expand Therapeutic Use Cases
- Inclusion of Gonorrhea Treatments in National Reimbursement Lists Improves Accessibility
- Regulatory Fast-Track Approvals for Novel Antimicrobials Encourage Industry Participation
- Expansion of Telehealth and Online Prescriptions Increases Market Reach of Therapeutic Providers
- Cross-Sector Collaboration with NGOs and Public Health Bodies Drives Distribution in Low-Income Regions
- Surveillance and Resistance Monitoring Systems Inform Pipeline and Post-Market Development
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Gonorrhea Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 3: World 6-Year Perspective for Gonorrhea Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
- TABLE 4: World Recent Past, Current & Future Analysis for Monotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 5: World 6-Year Perspective for Monotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 6: World Recent Past, Current & Future Analysis for Combination Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 7: World 6-Year Perspective for Combination Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 9: World 6-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 10: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 11: World 6-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 12: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 13: World 6-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Gonorrhea Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 14: USA Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 15: USA 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
- TABLE 16: USA Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 17: USA 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
- CANADA
- TABLE 18: Canada Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 19: Canada 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
- TABLE 20: Canada Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 21: Canada 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
- JAPAN
- Gonorrhea Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 22: Japan Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 23: Japan 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
- TABLE 24: Japan Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 25: Japan 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
- CHINA
- Gonorrhea Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 26: China Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 27: China 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
- TABLE 28: China Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 29: China 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
- EUROPE
- Gonorrhea Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 30: Europe Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 31: Europe 6-Year Perspective for Gonorrhea Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
- TABLE 32: Europe Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 33: Europe 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
- TABLE 34: Europe Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 35: Europe 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
- FRANCE
- Gonorrhea Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 36: France Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 37: France 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
- TABLE 38: France Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 39: France 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
- GERMANY
- Gonorrhea Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 40: Germany Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 41: Germany 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
- TABLE 42: Germany Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 43: Germany 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
- ITALY
- TABLE 44: Italy Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 45: Italy 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
- TABLE 46: Italy Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 47: Italy 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
- UNITED KINGDOM
- Gonorrhea Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 48: UK Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 49: UK 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
- TABLE 50: UK Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 51: UK 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
- REST OF EUROPE
- TABLE 52: Rest of Europe Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 53: Rest of Europe 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
- TABLE 54: Rest of Europe Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 55: Rest of Europe 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
- ASIA-PACIFIC
- Gonorrhea Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 57: Asia-Pacific 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
- TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 59: Asia-Pacific 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
- REST OF WORLD
- TABLE 60: Rest of World Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 61: Rest of World 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
- TABLE 62: Rest of World Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 63: Rest of World 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
IV. COMPETITION
